Developer docs
API playgroundTry for free, no card

Search company profiles

Kiffik Biomedical

Full company profile

uuid0002by9

Namestring
Kiffik Biomedical
Legal namestring
Kiffik Biomedical Inc.
Websiteurl
kiffik.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Kiffik Biomedical Inc. is a Miami-based, privately held molecular infrastructure company (Delaware corporation, founded 2018) that has developed the K-EXP™ platform — a proprietary technology enabling controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. ISF is the molecular environment surrounding living cells, and Kiffik's central claim is that biomarkers measured in ISF provide earlier biological visibility than those captured in blood after systemic circulation. Platform evaluations report that 25%+ of biomarkers observed in ISF datasets were not detected in matched plasma samples, with elevated stability in select ISF samples relative to plasma.

The K-EXP™ platform supports a range of applications spanning biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking. It is positioned for use across early discovery, clinical development, and real-world biology, with stated validation in oncology, neurology, and cardiometabolic disease, alongside adjacent applications in dermatology, cardiology, stress physiology, recovery, inflammatory signaling, and performance monitoring. K-EXP is explicitly labeled investigational use only and is not FDA cleared.

Kiffik generates revenue through platform licensing, research partnerships, and strategic alliances rather than direct product sales. Its customer base is enterprise-oriented and segmented across pharmaceutical and biotech research organizations, clinical development teams, medical device and diagnostic companies, beauty and animal health organizations, and academic/research institutions. The company distributes globally through partnerships, with a recently announced (March 2026) alliance with HekaBio K.K. covering Japan and the broader Asia-Pacific region. Go-to-market is primarily via direct outreach and a website contact form targeting investors, partners, providers, researchers, and consumers — consistent with a business-development-led enterprise sales motion. The company closed an oversubscribed Series A in December 2025 to fund clinical program expansion, manufacturing scale-up, and regulatory milestones.

Short descriptiontext

Kiffik Biomedical is a Miami-based molecular diagnostics company that has developed the proprietary K-EXP™ platform for non-invasive access to Interstitial Fluid (ISF), enabling earlier biomarker detection and longitudinal monitoring for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interstitial fluid diagnostics, biomarker discovery platform, molecular measurement technology, clinical development analytics, non-invasive biosensing
Industry4 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Licensing and Partnership Deals
TypeLicensing Royalties
Description

KIFFIK enables access to interstitial fluid for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations. Revenue appears to be generated through platform licensing, research partnerships, and strategic alliances. The company operates globally through partnerships across research, clinical, and industrial domains.

kiffik.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1K-EXP
Description

Real-time molecular diagnostics platform enabling controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. Supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking.

biospace.com
Core offering1 text field

Kiffik Biomedical develops the K-EXP™ platform, a proprietary molecular measurement technology that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. The platform supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across applications spanning early discovery, clinical development, and real-world biological monitoring in oncology, cardiology, neurology, and dermatology. The platform is offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing, research partnerships, and strategic alliances.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 25%+ biomarkers observed in ISF datasets not detected in matched plasma
+1 more record
Product overview1 text field

KIFFIK Biomedical offers a single unified product: the K-EXP™ platform. This core platform enables direct, non-invasive access to interstitial fluid (ISF) for molecular diagnostics and biomarker measurement, supporting applications across early discovery, clinical development, and real-world biological monitoring. The platform is designed for use across oncology, cardiology, neurology, and dermatology.

Product and service1 record
1K-EXP™ Platform
CategoryMolecular Diagnostics Platform
Description

A proprietary real-time molecular diagnostics platform that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. Supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across oncology, cardiology, neurology, and dermatology applications. Offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing and partnerships. KIFFIK EXP is not FDA cleared and is for investigational use only.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Strategic alliance to expand K-EXP interstitial fluid (ISF) molecular measurement platform across Japan and broader Asia-Pacific region. HekaBio will support KIFFIK's regulatory strategy in Japan, serve as a local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. The K-EXP platform enables direct access to interstitial fluid for biomarker detection across oncology, cardiology, neurology, and dermatology applications.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Profusa develops injectable, injectable hydrogel-based biosensors that continuously monitor multiple analytes in interstitial fluid. It is the most direct competitor to Kiffik's K-EXP, working in the same ISF biofluid, same continuous-monitoring paradigm, and same multi-analyte biomarker positioning.

TypeDirect peer
Description

Biolinq is developing intradermal biosensor patches that measure multiple analytes in interstitial fluid. Like Kiffik, Biolinq targets continuous, real-time, multi-biomarker monitoring from a minimally invasive skin-access platform, putting it in the same product category and customer use cases.

TypeBroad incumbent
Description

Dexcom is the dominant continuous glucose monitor company, with sensor technology that reads glucose from interstitial fluid. While Dexcom is glucose-only today, its scale, regulatory infrastructure, and stated multi-analyte ambitions make it the most material incumbent competing for the ISF molecular-monitoring future Kiffik is targeting.

TypeBroad incumbent
Description

Abbott's FreeStyle Libre franchise is the global volume leader in ISF-based continuous glucose sensing, with hundreds of millions of sensors shipped. Abbott is also investing in multi-analyte ISF sensing, putting it in direct conceptual competition with Kiffik's K-EXP at a much larger scale.

TypeBroad incumbent
Description

Senseonics markets Eversense, the only FDA-approved implantable continuous glucose monitor that sits in interstitial fluid for up to six months. It validates the ISF long-duration monitoring concept that underpins Kiffik's platform, while competing for the same clinical/regulatory lane.

6Epicore Biosystems
TypeEmerging player
Description

Epicore Biosystems develops sweat-based wearable biosensors for hydration, biomarkers, and metabolic monitoring. It is an emerging alternative-biofluid competitor addressing adjacent continuous molecular monitoring use cases that overlap with Kiffik's longitudinal biology tracking ambitions.

TypeBroad incumbent
Description

Medtronic is a major ISF continuous glucose monitoring incumbent through its diabetes business and is investing in broader continuous sensing. Its global sales force and hospital-channel relationships set a high bar for any emerging ISF platform company, including Kiffik.

TypeBroad incumbent
Description

Charles River Laboratories is a major preclinical and bioanalytical CRO that offers PK/PD, biomarker, and immunogenicity services — the same enterprise services that Kiffik is selling into pharma and biotech. It is a broad incumbent alternative for the same pharma/biotech budget dollars Kiffik targets.

TypeBroad incumbent
Description

IQVIA is a global clinical and bioanalytical CRO that provides PK/PD, biomarker assay, and clinical-trial-support services. It competes with Kiffik for the same pharma clinical development and translational biomarker budgets, albeit through a vastly broader service portfolio.

TypeOthers
Description

Quanterix provides ultra-sensitive single-molecule biomarker detection (Simoa) used in clinical research and pharma biomarker programs. While not an ISF platform, it is an enabling/competing biomarker-measurement technology that pharma customers may choose over Kiffik's K-EXP for ultra-sensitive protein biomarker discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kiffik Biomedical

Molecular Diagnostics Platformkiffik.com

Kiffik Biomedical is a Miami-based molecular diagnostics company that has developed the proprietary K-EXP™ platform for non-invasive access to Interstitial Fluid (ISF), enabling earlier biomarker detection and longitudinal monitoring for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations.

What Kiffik Biomedical does

Kiffik Biomedical Inc. is a Miami-based, privately held molecular infrastructure company (Delaware corporation, founded 2018) that has developed the K-EXP™ platform — a proprietary technology enabling controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. ISF is the molecular environment surrounding living cells, and Kiffik's central claim is that biomarkers measured in ISF provide earlier biological visibility than those captured in blood after systemic circulation. Platform evaluations report that 25%+ of biomarkers observed in ISF datasets were not detected in matched plasma samples, with elevated stability in select ISF samples relative to plasma.

The K-EXP™ platform supports a range of applications spanning biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking. It is positioned for use across early discovery, clinical development, and real-world biology, with stated validation in oncology, neurology, and cardiometabolic disease, alongside adjacent applications in dermatology, cardiology, stress physiology, recovery, inflammatory signaling, and performance monitoring. K-EXP is explicitly labeled investigational use only and is not FDA cleared.

Kiffik generates revenue through platform licensing, research partnerships, and strategic alliances rather than direct product sales. Its customer base is enterprise-oriented and segmented across pharmaceutical and biotech research organizations, clinical development teams, medical device and diagnostic companies, beauty and animal health organizations, and academic/research institutions. The company distributes globally through partnerships, with a recently announced (March 2026) alliance with HekaBio K.K. covering Japan and the broader Asia-Pacific region. Go-to-market is primarily via direct outreach and a website contact form targeting investors, partners, providers, researchers, and consumers — consistent with a business-development-led enterprise sales motion. The company closed an oversubscribed Series A in December 2025 to fund clinical program expansion, manufacturing scale-up, and regulatory milestones.

Kiffik Biomedical firmographics

Firmographics
Name
Kiffik Biomedical
Legal name
Kiffik Biomedical Inc.
Website
https://kiffik.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Kiffik Biomedical is a Miami-based molecular diagnostics company that has developed the proprietary K-EXP™ platform for non-invasive access to Interstitial Fluid (ISF), enabling earlier biomarker detection and longitudinal monitoring for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations.
Ownership category
akta.pro rank

Kiffik Biomedical industry classification

Industry
Product category
Molecular Diagnostics Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Interstitial fluid diagnostics
  • Biomarker discovery platform
  • Molecular measurement technology
  • Clinical development analytics
  • Non-invasive biosensing

Where Kiffik Biomedical is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kiffik Biomedical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Platform Licensing and Partnership Deals: KIFFIK enables access to interstitial fluid for pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations. Revenue appears to be generated through platform licensing, research partnerships, and strategic alliances. The company operates globally through partnerships across research, clinical, and industrial domains.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Kiffik Biomedical product offering

Product offering

Core offering

Kiffik Biomedical develops the K-EXP™ platform, a proprietary molecular measurement technology that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. The platform supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across applications spanning early discovery, clinical development, and real-world biological monitoring in oncology, cardiology, neurology, and dermatology. The platform is offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing, research partnerships, and strategic alliances.

Product overview

KIFFIK Biomedical offers a single unified product: the K-EXP™ platform. This core platform enables direct, non-invasive access to interstitial fluid (ISF) for molecular diagnostics and biomarker measurement, supporting applications across early discovery, clinical development, and real-world biological monitoring. The platform is designed for use across oncology, cardiology, neurology, and dermatology.

Differentiator

Problem solved

Functional benefit

Brands

  • K-EXP: Real-time molecular diagnostics platform enabling controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. Supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking.

Products and services

  • K-EXP™ Platform A proprietary real-time molecular diagnostics platform that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. Supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across oncology, cardiology, neurology, and dermatology applications. Offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing and partnerships. KIFFIK EXP is not FDA cleared and is for investigational use only.

Quantifiable outcome

  • 25%+ biomarkers observed in ISF datasets not detected in matched plasma
  • +1 more outcomes

Companies that use Kiffik Biomedical

Customer profile

Segments5 records

Ideal customer profiles4 records

Kiffik Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kiffik Biomedical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HekaBio K.K.coreStrategic or Co-development Partner · 24 March 2026Strategic alliance to expand K-EXP interstitial fluid (ISF) molecular measurement platform across Japan and broader Asia-Pacific region. HekaBio will support KIFFIK's regulatory strategy in Japan, serve as a local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. The K-EXP platform enables direct access to interstitial fluid for biomarker detection across oncology, cardiology, neurology, and dermatology applications.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Kiffik Biomedical competitors and assessment

Company assessment

Direct peers

  • Profusa: Profusa develops injectable, injectable hydrogel-based biosensors that continuously monitor multiple analytes in interstitial fluid. It is the most direct competitor to Kiffik's K-EXP, working in the same ISF biofluid, same continuous-monitoring paradigm, and same multi-analyte biomarker positioning.
  • Biolinq: Biolinq is developing intradermal biosensor patches that measure multiple analytes in interstitial fluid. Like Kiffik, Biolinq targets continuous, real-time, multi-biomarker monitoring from a minimally invasive skin-access platform, putting it in the same product category and customer use cases.

Broad incumbents

  • Dexcom: Dexcom is the dominant continuous glucose monitor company, with sensor technology that reads glucose from interstitial fluid. While Dexcom is glucose-only today, its scale, regulatory infrastructure, and stated multi-analyte ambitions make it the most material incumbent competing for the ISF molecular-monitoring future Kiffik is targeting.
  • Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre franchise is the global volume leader in ISF-based continuous glucose sensing, with hundreds of millions of sensors shipped. Abbott is also investing in multi-analyte ISF sensing, putting it in direct conceptual competition with Kiffik's K-EXP at a much larger scale.
  • Senseonics: Senseonics markets Eversense, the only FDA-approved implantable continuous glucose monitor that sits in interstitial fluid for up to six months. It validates the ISF long-duration monitoring concept that underpins Kiffik's platform, while competing for the same clinical/regulatory lane.
  • Medtronic: Medtronic is a major ISF continuous glucose monitoring incumbent through its diabetes business and is investing in broader continuous sensing. Its global sales force and hospital-channel relationships set a high bar for any emerging ISF platform company, including Kiffik.
  • Charles River Laboratories: Charles River Laboratories is a major preclinical and bioanalytical CRO that offers PK/PD, biomarker, and immunogenicity services — the same enterprise services that Kiffik is selling into pharma and biotech. It is a broad incumbent alternative for the same pharma/biotech budget dollars Kiffik targets.
  • IQVIA: IQVIA is a global clinical and bioanalytical CRO that provides PK/PD, biomarker assay, and clinical-trial-support services. It competes with Kiffik for the same pharma clinical development and translational biomarker budgets, albeit through a vastly broader service portfolio.

Emerging players

  • Epicore Biosystems: Epicore Biosystems develops sweat-based wearable biosensors for hydration, biomarkers, and metabolic monitoring. It is an emerging alternative-biofluid competitor addressing adjacent continuous molecular monitoring use cases that overlap with Kiffik's longitudinal biology tracking ambitions.

Others

  • Quanterix: Quanterix provides ultra-sensitive single-molecule biomarker detection (Simoa) used in clinical research and pharma biomarker programs. While not an ISF platform, it is an enabling/competing biomarker-measurement technology that pharma customers may choose over Kiffik's K-EXP for ultra-sensitive protein biomarker discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Kiffik Biomedical social profiles

Digital presence

Kiffik Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kiffik Biomedical leadership team

Management profile

Number of profiles

Profiles3 records

Kiffik Biomedical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kiffik Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kiffik Biomedical

What does Kiffik Biomedical do?

Kiffik Biomedical develops the K-EXP™ platform, a proprietary molecular measurement technology that enables controlled, non-invasive access to Interstitial Fluid (ISF) for repeat biological measurement. The platform supports biomarker discovery, longitudinal monitoring, therapeutic response evaluation, PK/PD measurement, and dynamic physiology tracking across applications spanning early discovery, clinical development, and real-world biological monitoring in oncology, cardiology, neurology, and dermatology. The platform is offered to pharmaceutical, diagnostic, medical device, beauty, animal health, and research organizations through licensing, research partnerships, and strategic alliances.

Is Kiffik Biomedical a public or private company?

Kiffik Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kiffik Biomedical founded?

Kiffik Biomedical was founded in 2021. It employs 11 to 50 people.

Where is Kiffik Biomedical based?

Kiffik Biomedical is headquartered in Miami, United States, in the North America region.

How does Kiffik Biomedical make money?

One revenue line is on record: platform Licensing and Partnership Deals.

Who are Kiffik Biomedical's main competitors?

Direct peers on record are Profusa and Biolinq. Broad incumbents are Dexcom, Abbott Diabetes Care (FreeStyle Libre), Senseonics, Medtronic, Charles River Laboratories and IQVIA. Epicore Biosystems is listed as an emerging player. Quanterix is listed as an others.

Does Kiffik Biomedical have an API?

No public API is recorded for Kiffik Biomedical.

What industry is Kiffik Biomedical in?

Kiffik Biomedical's product category is Molecular Diagnostics Platform. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAEAG, Bioanalytical & PK/PD Sample Analysis (Trial Support). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageKIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences ReviewKIFFIK Biomedical was named Top Biomarker Access Technology 2026 by Life Sciences Review, featuring its K-EXP platform for non-invasive interstitial fluid access. The company aims to expand practical access to biological information for biomarker discovery and drug development.FinancialContent Business PageKIFFIK Biomedical Appoints Dr. Mark Vreeke as Chief Technology OfficerKIFFIK Biomedical Inc. announced the appointment of Dr. Mark Vreeke as Chief Technology Officer, effective immediately. Dr. Vreeke brings more than three decades of experience in biosensor and medical device development, including his work as an early member of the TheraSense team, whose technology was ultimately acquired by Abbott. As CTO, he will lead KIFFIK's technology strategy, product development, and advancement of the company's K-EXP™ platform, which is expected to be available in late 2026 for select clinical partner programs.MorningstarRenowned Life Science Leader Dr. Gino Martini Joins KIFFIK Biomedical as Chief Scientific OfficerKIFFIK Biomedical appointed Dr. Gino Martini as Chief Scientific Officer, bringing experience from GSK, Roche, and Shire. The company's non-invasive K-EXP platform is expected to launch in late 2026, with clinical studies planned for Q4 2026.BioSpaceKIFFIK Biomedical Establishes Strategic Partnership with Beacon MedTech Solutions to Commercialize its K-EXP(TM) PlatformKIFFIK Biomedical announced a manufacturing partnership with Beacon MedTech Solutions to commercialize its K-EXP platform. The clinical device is expected in the second half of 2026, with scalable production starting mid-2027. The partnership aims to compress validation to scale and support partner programs.PharmiWeb.comKIFFIK Biomedical and HekaBio Announce Strategic Alliance to Expand ISF-Based Molecular Access Across Asia-PacificKIFFIK Biomedical announced a strategic alliance with HekaBio K.K. to expand its K-EXP™ interstitial fluid (ISF) molecular measurement platform across Japan and the broader Asia-Pacific region. Under the agreement, HekaBio will support KIFFIK's regulatory strategy in Japan, serve as a local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. The K-EXP platform enables direct access to interstitial fluid for biomarker detection across oncology, cardiology, neurology, and dermatology applications.CincinnatiKIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics PlatformKIFFIK Biomedical announced the successful close of its oversubscribed Series A financing, which was completed ahead of schedule. This funding will support the expansion of its K-EXP™ platform and advance clinical programs in oncology, neurology, and cardiometabolic disease, reflecting investor confidence in the future of continuous, real-time diagnostics.Naples Daily NewsKIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics PlatformKIFFIK Biomedical has successfully closed an oversubscribed Series A financing round ahead of schedule to advance its real-time molecular diagnostics platform, the K-EXP. The proceeds will support the expansion of the platform, accelerate manufacturing scale-up, and advance five active clinical programs in oncology, neurology, and cardiometabolic disease. This funding validates investor confidence in shifting diagnostics from static testing to continuous molecular monitoring.USA TODAYKIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics PlatformKIFFIK Biomedical has closed its Series A financing ahead of schedule, with the round being significantly oversubscribed by global strategic investors. The company intends to use the proceeds to expand its proprietary K-EXP™ real-time molecular diagnostics platform and advance five active clinical programs in oncology, neurology, and cardiometabolic disease.York Daily RecordKIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics PlatformKIFFIK Biomedical announced the successful closing of its oversubscribed Series A financing round to support the development and commercial expansion of its real-time molecular diagnostics platform, K-EXP. The funding will be used to advance clinical programs, expand manufacturing, and meet regulatory milestones, reflecting strong investor confidence in the platform's potential for continuous, real-time biological measurement.Ventura County StarKIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics PlatformKIFFIK Biomedical announced the successful close of its oversubscribed Series A financing, which was completed ahead of schedule, indicating strong investor confidence in continuous, real-time diagnostics. The funds will support the expansion of KIFFIK’s K-EXP™ platform and advance five active clinical programs across various diseases. This move highlights a shift in diagnostics towards continuous molecular intelligence, aiming for earlier disease detection and optimized therapies.